Compounds that inhibit the re-uptake and/or metabolism of biogenic amines (
i.e. serotonin, norepinephrine, and dopamine) have been used to treat depre
ssion for more than CO years, Selective re-uptake inhibitors, currently the
most widely prescribed class of biogenic amine-based agents, are certainly
safe and relatively easy to use, but do not exhibit either a faster onset
of action or greater efficacy than their predecessors. An approach to overc
ome the limitations that may be inherent to these 'conventional' therapies
is to circumvent the monoaminegic synapse. In this review, two potential an
tidepressant strategies are discussed that may converge with intracellular
pathways impacted by chronic treatment with biogenic amine-based agents. Dr
ugs emerging from these strategies may offer significant advantages over cu
rrently used antidepressants. (C) 2001 Academic Press.